Neurology Articles

Neurology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Panconesi A et al. – The authors observed a low percentage of triptan users and a low rate of utilization, associated with a high percentage of discontinuation and new utilization (high turnover), without any substantial increase in triptans utilization during the years. All these data probably do not support optimal satisfaction with triptan therapy.

Related Articles

Clinical and Economic Comparison of Frovatriptan Versus other Oral Triptans in the Treatment of Acute Migraine in the Real-World Setting
Clinical Drug Investigation, 10/15/09    Relevance Score: 92%

Safety and Tolerability of Short-Term Preventive Frovatriptan: A Combined Analysis
Headache: The Journal of Head and Face Pain, 10/15/09    Relevance Score: 80%

Expanding Access to Triptans: Assessment of Clinical Outcome
Headache: The Journal of Head and Face Pain, 10/12/09    Relevance Score: 80%

New drugs for migraine
The Journal of Headache and Pain, 10/05/09    Relevance Score: 80%

Postmarketing migraine survey of frovatriptan: effectiveness and tolerability vs previous triptans, NSAIDs or a combination
Current Medical Research and Opinion, 10/01/09    Relevance Score: 80%

Today in Headache...keeping you current

Epidemiology of headache in Arab countries
The Journal of Headache and Pain, 12/04/09

Economic Evaluation of Pharmacotherapy of Migraine Pain: A Review of the Literature
Journal Of Pain & Palliative Care Pharmacotherapy, 12/02/09

The validity of questionnaire-based diagnoses: the third Nord-Trondelag Health Study 2006-2008
The Journal of Headache and Pain, 12/01/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address